HUTCHMED (China) Limited American Depositary Shares (HCM)
Stock · NASDAQ · Health Care
$12.4as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$12.47
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $2.06B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
HUTCHMED (China) Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- HCMHUTCHMED (China) Limited American Depositary Shares$12.4▼ 0.12%Market cap $2.06BP/E —
- STOKStoke Therapeutics Inc. Common Stock$31.61▼ 3.01%Market cap $2.06BP/E —$18.8$40.22
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.3▼ 1.09%Market cap $2.10BP/E 6.39$10.34$19.25
- ZBIOZenas BioPharma Inc. Common Stock$31.29▼ 4.08%Market cap $2.03BP/E —$13.5$44.6
- NUVBNuvation Bio Inc. Class A Common Stock$6.67▼ 4.65%Market cap $2.13BP/E —$2.87$9.75
- BHVNBiohaven Ltd. Common Shares$15.42▼ 4.37%Market cap $2.17BP/E —$7.48$18.57
- SLSSELLAS Life Sciences Group Inc. Common Stock$13.17▼ 13.45%Market cap $2.18BP/E —
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | — | $12.4 | ▼ 0.12% | |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $31.61 | ▼ 3.01% | $18.8$40.22 |
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 6.39 | $16.3 | ▼ 1.09% | $10.34$19.25 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $31.29 | ▼ 4.08% | $13.5$44.6 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $6.67 | ▼ 4.65% | $2.87$9.75 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $15.42 | ▼ 4.37% | $7.48$18.57 |
| SLS SELLAS Life Sciences Group Inc. Common Stock | $2.18B | — | $13.17 | ▼ 13.45% |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinomabenzinga · 8/28/2026
- AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal StudiesBenzinga · 8/17/2026
- Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung CancerBenzinga · 8/17/2026
Insider Activity
Insider Actions →Acquired
293.6K
Disposed
0
- Cheng Chig Fung · May 20, 2026 · J26.3K
- Cheng Chig Fung · May 20, 2026 · J30.2K
- Nixon Charles George Rupert · May 20, 2026 · J7.6K
- Nixon Charles George Rupert · May 20, 2026 · J7.4K
- Su Wei-guo · May 20, 2026 · J75.1K
- Su Wei-guo · May 20, 2026 · J132.9K
- Chiu Lorenso · May 20, 2026 · J8.9K
- Chiu Lorenso · May 20, 2026 · J5.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.27M
- Total value held
- $63.57M
- Institutional holders
- 52
Top holders this quarter
- Unknown1.48M
- Unknown837.5K
- Unknown304.8K
- Unknown291.2K
- Unknown255.5K
- Unknown232.2K
- Unknown132.1K
- Unknown106.5K
- Unknown85.0K
- Unknown76.5K
See the full, filterable feed with live charts on the MarketWall dashboard.